699856 | FP-18, sodium salt
(2R,3R,4R,5S,6R)-3-dodecanamido-4,5-bis(dodecanoyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl phosphate, sodium salt
FP-18, sodium salt
(2R,3R,4R,5S,6R)-3-dodecanamido-4,5-bis(dodecanoyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl phosphate, sodium salt
FP adjuvants, particularly FP-18 and FP-20, offer another innovative approach to boosting vaccine efficacy by selectively stimulating Toll-like receptor 4 (TLR4) pathways. The simplicity of FP structures allows for scalable production of highly pure materials, ensuring a reliable and cost-effective supply for vaccine developers. Like VSA, FP adjuvants provide both humoral and cellular immune enhancements but achieve this through a targeted, mechanism-driven approach. FP-18 activates the MyD88-dependent pathway, leading to the release of critical cytokines such as TNFα, IL-1β, and IL-6. It also stimulates the TRIF-dependent pathway, which promotes a Type 1 interferon (IFN) signature, an essential component for antiviral responses.
FP-18, sodium salt (and other FP compounds) have been licensed through a third-party. This compound is intended for research purposes only. If you wish to discuss a potential sub-license, please reach out via email to customerservice@avantilipids.com.
C42H78NNa2O11P
C 59.35%, H 9.25%, H 1.65%, Na 5.41%, O 20.70%, P 3.64%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozJ. Med. Chem. 2023, 66, 4, 3010–3029Publication Date:February 2, 2023https://doi.org/10.1021/acs.jmedchem.2c01998
ACS Omega 2023, 8, 39, 36412–36417Publication Date:September 18, 2023https://doi.org/10.1021/acsomega.3c05363
J. Med. Chem. 2021, 64, 16, 12261–12272Publication Date:August 12, 2021https://doi.org/10.1021/acs.jmedchem.1c00896
- Certificate of Analysis (Lot No. 699856P-10MG-A-010 and 7187PIA010)
